作者: Holak, Tad A. ; Sitar, Tomasz ; Kitel, Radoslaw ; Bielski, Przemyslaw ; Musielak, Bogdan ; Barczynski, Jan ; Tyrcha, Urszula ; Hec-Galazka, Aleksandra ; Plewka, Jacek ; Mikitiuk, Michal ; Gudz, Ganna P.

Therapeutic antibodies directed against either programmed cell death-1 protein (PD-1) or its ligand PD-L1 have demonstrated efficacy in the treatment of various cancers.In contrast with antibodies, small mols. have the potential for increased tissue penetration; better pharmacol.; and therefore, improved antitumor activity.A series of nonsym. C2 inhibitors were synthesized and evaluated for PD-1/PD-L1 interaction inhibition.These compounds induced PD-L1 dimerization and effectively blocked PD-L1/PD-1 interaction in a homogeneous time-resolved fluorescence (HTRF) assay with most inhibitors exhibiting IC50 values in the single-digit nM range and below.Their high inhibitory potency was also demonstrated in a cell-based coculture PD-1 signaling assay where 2 exhibited an EC50 inhibitory activity of 21.8 nM, which approached that of the PD-L1 antibody durvalumab (EC50 = 0.3-1.8 nM).Structural insight into how these inhibitors interact with PD-L1 was gained by using NMR and X-ray cocrystal structure studies.These data support further preclin. evaluation of these compounds as antibody alternatives.

2021-05-01·The Lancet Haematology1区 · 医学

Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial

1区 · 医学

Article

作者: Benajiba, Lina ; Soret, Juliette ; Junge, Guido ; End, Peter ; Risitano, Antonio M ; Peffault de Latour, Régis ; Nidamarthy, Prasanna K ; Milojevic, Julie ; Frieri, Camilla ; Röth, Alexander ; de Fontbrune, Flore Sicre ; Marotta, Serena ; Rozenberg, Izabela ; Marano, Luana ; Alashkar, Ferras

BACKGROUNDThe haematological benefit of standard-of-care anti-C5 treatment for haemolytic paroxysmal nocturnal haemoglobinuria is limited by residual intravascular haemolysis or emerging C3-mediated extravascular haemolysis. Therefore, the aim of this phase 2 study was to assess the safety, tolerability, pharmacokinetics and pharmacodynamics, and activity of the new complement factor B inhibitor, iptacopan, in patients with paroxysmal nocturnal haemoglobinuria who have active haemolysis despite anti-C5 therapy.METHODSIn this multicentre, open-label, single-arm, phase 2 trial, we enrolled adult patients (aged 18-80 years) with paroxysmal nocturnal haemoglobinuria who showed signs of active haemolysis despite receiving eculizumab treatment. Patients were enrolled at Federico II University Hospital (Naples, Italy), Hôpital Saint-Louis (Paris, France), and University Hospital Essen (Essen, Germany). For enrolment, patients were required to show lactate dehydrogenase more than 1·5-times the upper limit of normal and a paroxysmal nocturnal haemoglobinuria type 3 erythrocyte or granulocyte clone size of 10% or greater. Patients with bone marrow failure, on systemic steroid or immunosuppressive drugs, or with severe comorbidities were excluded from the study. Iptacopan was given orally as an add-on therapy at a dose of 200 mg twice daily. The primary endpoint was the effect of iptacopan on the reduction of chronic residual intravascular haemolysis measured as change in lactate dehydrogenase from baseline value to week 13. At 13 weeks, patients could opt into a long-term study extension (ongoing), allowing for modifications of standard treatment. This trial is registered at ClinicialTrials.gov, NCT03439839.FINDINGSBetween May 31, 2018, and April 9, 2019, ten patients had twice daily 200 mg iptacopan. Iptacopan resulted in marked reduction of lactate dehydrogenase from baseline versus at week 13 (mean 539 IU/L [SD 263] vs 235 IU/L [44], change from baseline -309·2 IU/L [SD 265·5], 90% CI -473·77 to -144·68, p=0·0081), associated with significant improvement of haemoglobin concentrations (mean 97·7 g/L [SD 10·5] vs 129·5 g/L [18·3] change from baseline 31·9 g/L [14·5], 90% CI 23·42-40·28, p<0·0001). All biomarkers of haemolysis improved on iptacopan treatment. Observed haematological benefits were maintained longer than the 13-week study period, throughout the study extension, including seven patients who stopped concomitant standard-of-care treatment and continued iptacopan as monotherapy. There were no deaths or treatment-related serious adverse events during the study period. Of three non-related serious adverse events, two occurred in the same patient (one during run-in and before exposure to iptacopan).INTERPRETATIONIptacopan at a chronic dose of 200 mg twice daily was well tolerated without any major drug-related safety findings and shows lactate dehydrogenase reduction and haemoglobin normalisation in most patients with paroxysmal nocturnal haemoglobinuria at week 13 and beyond, even in monotherapy. On the basis of these data, iptacopan will be tested as monotherapy in pivotal trials investigating its haematological benefit in a broader paroxysmal nocturnal haemoglobinuria population.FUNDINGNovartis Institutes for Biomedical Research.

2014-04-24·Blood1区 · 医学

Decrypting C2 inhibitors

1区 · 医学

Article

作者: Voorberg, Jan ; Meems, Henriët

A review.In this issue of Blood, Nguyen et al employ high-resolution mapping to precisely define epitopes on the C2 domain of blood coagulation factor VIII (FVIII).Their results nicely complement a recent report in Blood describing the structure of a ternary complex of 2 inhibitory antibodies with the C2 domain.Together, these studies reveal fascinating mol. details on the unexpectedly large number of exposed surfaces in the C2 domain that contribute to the binding of inhibitory antibodies.These findings are relevant in the context of neutralizing anti-FVIII antibodies that develop in patients with hemophilia A.Insight into the antigenic properties of the C2 domain is needed to design FVIII variants with decreased antigenicity.Pioneering studies by Dorothea Scandella on the epitope mapping of FVIII inhibitors already pointed toward the C2 domain as a major binding site for FVIII inhibitors.The recent studies by Nguyen and Walter, combined with earlier work by Meeks et al, have provided evidence for 3 major binding sites for inhibitory anti-FVIII antibodies within the C2 domain.The overall dimensions of the C2 domain are small when compared to antibodies.Nevertheless, at least 2 and probably 3 monoclonal antibodies can simultaneously bind to the C2 domain.The mapping studies reported by Nguyen also suggest the presence of 3 distinct clusters of surface-exposed side chains on the FVIII C2 domain (see figure).

100 项与 Oral C2 Inhibitor 相关的药物交易

登录后查看更多信息